Key result
QiShenYiQi Pills relieved fatigue-induced cardiac hypertrophy and enhanced heart function in a rat model, potentially by improving energy metabolism through IGF-1R signaling regulation.
Why the study?
Prolonged exercise can adversely affect cardiac function, but whether QiShenYiQi Pills can ameliorate fatigue-induced cardiac hypertrophy through energy regulation was unknown.
Does QiShenYiQi Pills (QSYQ) ameliorate fatigue-induced cardiac hypertrophy and dysfunction in a rat model?
Does QiShenYiQi Pills (QSYQ) ameliorate fatigue-induced cardiac hypertrophy and dysfunction in a rat model?
In a rat model, QiShenYiQi Pills ameliorated fatigue-induced cardiac hypertrophy and dysfunction by regulating energy metabolism via IGF-1R signaling.
Answers are grounded in this paper and cite their sources.
QSYQ may mitigate fatigue-induced hypertrophy in rats; leaves open human relevance and requires clinical trials.
Prolonged exercise and exercise training can adversely affect cardiac function in some individuals. QiShenYiQi Pills (QSYQ), which are a compound Chinese medicine, have been previously shown to improve pressure overload-induced cardiac hypertrophy. We hypothesized that QSYQ can ameliorate as well the fatigue-induced cardiac hypertrophy. This study was to test this hypothesis and underlying mechanism with a focus on its role in energy regulation. Male Sprague-Dawley rats were used to establish exercise adaptation and fatigue model on a motorized rodent treadmill. Echocardiographic analysis and heart function test were performed to assess heart systolic function. Food-intake weight/body weight and heart weight/body weight were assessed, and hematoxylin and eosin staining and immunofluorescence staining of myocardium sections were performed. ATP synthase expression and activity and ATP, ADP, and AMP levels were assessed using Western blot and ELISA. Expression of proteins related to energy metabolism and IGF-1R signaling was determined using Western blot. QSYQ attenuated the food-intake weight/body weight decrease, improved myocardial structure and heart function, and restored the expression and distribution of myocardial connexin 43 after fatigue, concomitant with an increased ATP production and a restoration of metabolism-related protein expression. QSYQ upgraded the expression of IGF-1R, P-AMPK/AMPK, peroxisome proliferator-activated receptor-γ coactivator-1α, nuclear respiratory factor-1, P-phosphatidylinositol 3-kinase (PI3K)/PI3K, and P-Akt/Akt thereby attenuated the dysregulation of IGF-1R signaling after fatigue. QSYQ relieved fatigue-induced cardiac hypertrophy and enhanced heart function, which is correlated with its potential to improve energy metabolism by regulating IGF-1R signaling. NEW & NOTEWORTHY Prolonged exercise may impact some people leading to pathological cardiac hypertrophy. This study using an animal model of fatigue-induced cardiac hypertrophy provides evidence showing the potential of QiShenYiQi Pills, a novel traditional Chinese medicine, to prevent the cardiac adaptive hypertrophy from development to pathological hypertrophy and demonstrates that this effect is correlated with its capacity for regulating energy metabolism through interacting with insulin-like growth factor-1 receptor.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2019) studied Fatigue-induced cardiac hypertrophy. QiShenYiQi Pills (QSYQ) vs. Fatigue model without QSYQ was evaluated on Cardiac hypertrophy and heart function. QiShenYiQi Pills relieved fatigue-induced cardiac hypertrophy and enhanced heart function in a rat model, potentially by improving energy metabolism through IGF-1R signaling regulation.
Synapse has enriched 10 related papers. Consider them for comparative context: